Interchangeable Biologics Clarity Act

United States117th CongressS-4303Senate
Updated: May 25, 2022

Summary

Interchangeable Biologics Clarity Act This bill provides a statutory definition for first interchangeable biosimilar biological product and makes other technical changes with respect to the provisions that establish the corresponding periods of market exclusivity.

Bill texts

Available versions
Introduced (Senate)View official text

1 version available

All available records shown.

Timeline

  1. Introduced in Senate

  2. Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709-2710)

    Senate

All available records shown.